Shlomo Dagan, Ph.D., CEO
Dr. Shlomo Dagan has served as the CEO of Andromeda since the establishment of the Company in 2007. He brings years of comprehensive and proven experience in the area of biotechnology to the Company. Prior to joining Andromeda, Dr. Dagan acted as the Chief Scientific Officer at Rosetta Genomics where he developed microRNA-based products for diagnosis and therapeutics. Before that, Dr. Dagan served as Chief Scientific Officer at XTL Biopharmaceuticals. During this time, he led the development, production and clinical trials of human monoclonal antibodies and small molecules for the treatment of viral hepatitis utilizing his expertise in the areas of Immunology, Molecular Biology and Virology. Dr. Dagan’s additional senior management positions include directing a Molecular Biology group at ImClone Systems and serving as the Head of the Clinical Reagents Department at Sigma Immunochemicals in Israel.
Dr. Dagan received his Ph.D. from the Weizmann Institute of Science in Israel.
Chaim Eldar, CFO
Chaim Eldar brings his business expertise in the area of financial management, operations, manufacturing, and strategic planning to Andromeda. Before joining Andromeda, Mr. Eldar was the CFO of T.D.A. Holding Ltd. where he oversaw financial planning, budget control and cash flow analysis of the company. Prior to this, Mr. Eldar served as the Regional CFO of Electra in East Asia where he managed the entire Finance, IT, and Custom and Legal Departments of Electra both in Hong Kong and China. During this time, he implemented the financial systems, developed the company finance policies and procedures in order to ensure more cost efficient and profitable business operations.
Mr. Eldar holds a CPA license from the Israeli Auditing Association and holds a MBA from Bar Ilan University, Israel.
Rachel Eren, Ph.D., MHA, VP Clinical Development
Dr. Rachel Eren joined Andromeda in 2009 bringing her experience in drug development, pre-clinical and clinical development to the Company. Prior to joining Andromeda, Dr. Eren served as VP R&D at Intellect Neurosciences, Inc and before that, as VP Pre-Clinical Development at XTL Biopharmaceuticals. During this time, she was involved in the development, production, and clinical trials of human monoclonal antibodies and small molecules for the treatment of Alzheimer's disease and viral hepatitis.
Dr. Eren has a scientific background in Immunology and she holds a Ph.D. in Immunology; a M.Sc. in Biophysics from the Weizmann Institute of Science; and a Masters Degree in Health Administration from the Department of Health Systems Management, Ben Gurion University.
Dana Elias, Ph.D., Strategic Planning and Program Director
Dr. Dana Elias joined Andromeda in 2007 serving as the Strategic Planning and Program Director bringing her expertise and vast knowledge in the field of diabetes to the company. Prior to Andromeda, Dr. Elias worked at Develogen, Israel as the VP and Global DiaPep277 Director where she was responsible and intricately involved in the development of a drug for treating type 1 diabetes. Preceding Develogen, Dr. Elias was the Director of Research and Development; Vice President of Research and Development and Senior VP and CTO at Peptor. Prior to Peptor, Dr. Elias was a Senior Scientist at Portman Pharmaceuticals. Throughout her work, Dr. Elias has played a major role in liaising with regulatory agencies such as the FDA and the EMEA.
Dr. Elias has a scientific background in Endocrinology and Immunology with a focus on autoimmune type 1 diabetes research. She holds a Ph.D. in Immunology and a M.Sc. in Hormone Research from the Weizmann Institute of Science.
Merana Tamir, Ph.D., Project Manager
Dr. Merana Tamir joined Andromeda in June 2007 as the Project Manager bringing her in depth management experience in the area of clinical trials. Before Andromeda, Dr. Tamir worked as the Manager of QA & Clinical Studies at Develogen, Israel. Prior to Develogen, Dr. Tamir served as the Head of Clinical Immunology and Project Manager at Peptor, Israel where she was responsible for managing a clinical lab and working in cooperation with Aventis as a member of a joint Global Development Team. Dr. Tamir also served as the Clinical and General Project Manager at Portman Pharmaceutical Industries Ltd.
Dr. Tamir holds a M.Sc. and Ph.D. from the Weizmann Institute of Science and Post Doctorate Fellowship from NYU (New York University) and the Institute of Alternative Thinking, University of Tel Aviv.